Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies

Basit Öğe Kaydı
dc.authoridDemircioğlu, Sinan/0000-0003-1277-5105
dc.authoridYagci, Munci/0000-0002-0458-2920
dc.authoridGuler, Nil/0000-0003-0604-6475
dc.authoridAr, Muhlis Cem/0000-0002-0332-9253
dc.authoridYavuz, Boran/0000-0002-3799-0461
dc.authoridCengiz Seval, Guldane/0000-0001-9433-2054
dc.authoridcivriz bozdağ, sinem/0000-0001-8359-7794
dc.authorwosidDemircioğlu, Sinan/AAF-9901-2020
dc.authorwosidYagci, Munci/ITT-2117-2023
dc.authorwosidGuler, Nil/ABE-4485-2021
dc.authorwosidAr, Muhlis Cem/S-7530-2016
dc.authorwosidaydın kaynar, lale/GLU-6163-2022
dc.authorwosidYavuz, Boran/GRJ-1596-2022
dc.authorwosidCengiz Seval, Guldane/GXV-6155-2022
dc.contributor.authorBozdag, Sinem Civriz
dc.contributor.authorSeval, Guldane Cengiz
dc.contributor.authorHindilerden, Ipek Yonal
dc.contributor.authorHindilerden, Fehmi
dc.contributor.authorAndic, Neslihan
dc.contributor.authorBaydar, Mustafa
dc.contributor.authorKaynar, Lale Aydin
dc.date.accessioned2024-08-04T20:10:09Z
dc.date.available2024-08-04T20:10:09Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly immunosuppressed populations, such as in patients with hematological malignancies, is a point of interest. We aimed to analyze the symptoms, complications, intensive care unit admissions, and mortality rates of patients with hematological malignancies infected with SARS-CoV-2 in Turkey. Materials and Methods: In this multicenter study, we included 340 adult and pediatric patients diagnosed with SARS-CoV-2 from March to November 2020. Diagnosis and status of primary disease, treatment schedules for hematological malignancies, time from last treatment, life expectancy related to the hematological disease, and comorbidities were recorded, together with data regarding symptoms, treatment, and outcome of SARS-CoV-2 infection. Results: Forty four patients were asymptomatic at diagnosis of SARSCoV-2 infection. Among symptomatic patients, fever, cough, and dyspnea were observed in 62.6%, 48.8%, and 41.8%, respectively. Sixtynine (20%) patients had mild SARS-CoV-2 disease, whereas moderate, severe, and critical disease was reported in 101 (29%), 71 (20%), and 55 (16%) patients, respectively. Of the entire cohort, 251 (73.8%) patients were hospitalized for SARS-CoV-2. Mortality related to SARS-CoV-2 infection was 26.5% in the entire cohort; this comprised 4.4% of those patients with mild disease, 12.4% of those with moderate disease, and 83% of those with severe or critical disease. Active hematological disease, lower life expectancy related to primary hematological disease, neutropenia at diagnosis of SARS-CoV-2, ICU admission, and first-line therapy used for coronavirus disease-2019 treatment were found to be related to higher mortality rates. Treatments with hydroxychloroquine alone or in combination with azithromycin were associated with a higher rate of mortality in comparison to favipiravir use. Conclusion: Patients with hematological malignancy infected with SARS-CoV-2 have an increased risk of severe disease and mortality.en_US
dc.identifier.doi10.4274/tjh.galenos.2021.2021.0287
dc.identifier.endpage54en_US
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue1en_US
dc.identifier.pmid34521187en_US
dc.identifier.scopus2-s2.0-85125212090en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage43en_US
dc.identifier.trdizinid522061en_US
dc.identifier.urihttps://doi.org/10.4274/tjh.galenos.2021.2021.0287
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/522061
dc.identifier.urihttps://hdl.handle.net/11616/92628
dc.identifier.volume39en_US
dc.identifier.wosWOS:000761303000006en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofTurkish Journal of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjectSARS-CoV-2 infectionen_US
dc.subjectHematological malignancyen_US
dc.titleClinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignanciesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu